£20 a share more like £50 plus a share I am greedy27 Jul 2022 00:42
SCHeckler ....Blood cancers um dont we have something sat on the shelf for that ,,,,FLT3 Kinase
Sareum has used its SKIL platform to develop a novel chemical series that inhibits the activity of FLT3 kinase and is highly selective against a panel of other kinases. These have potential use against certain types of leukaemia as well as autoimmune disorders such as Rheumatoid Arthritis and Multiple Sclerosis.